Even as Novartis CEO Vas Narasimhan works through a companywide restructuring, the chief exec saw his pay decline substantially in 2022 thanks to demerits on the company’s shareholder return scorecard.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,